These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 34099212)

  • 61. PD166326, a novel tyrosine kinase inhibitor, has greater antileukemic activity than imatinib mesylate in a murine model of chronic myeloid leukemia.
    Wolff NC; Veach DR; Tong WP; Bornmann WG; Clarkson B; Ilaria RL
    Blood; 2005 May; 105(10):3995-4003. PubMed ID: 15657179
    [TBL] [Abstract][Full Text] [Related]  

  • 62. A retrospective study of the prescribing and outcomes of tyrosine kinase inhibitors in chronic myeloid leukaemia over a period of more than 10 years.
    Lang AS; Mounier M; Roques M; Chretien ML; Boulin M
    J Clin Pharm Ther; 2015 Aug; 40(4):391-7. PubMed ID: 25865674
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Association of tuberculosis in patients with chronic myeloid leukemia: a treatment proposal based on literature review.
    Iqbal P; Soliman A; De Sanctis V; Yassin MA
    Expert Rev Hematol; 2021 Feb; 14(2):211-217. PubMed ID: 33433245
    [No Abstract]   [Full Text] [Related]  

  • 64. Bullous Pemphigoid Occurring after Stopping Imatinib Therapy of CML: Is a Continuation of Post-Treatment Follow-Up Needed?
    Yakobson A; Neime AE; Abu Saleh O; Al Athamen K; Shalata W
    Clin Pract; 2023 Sep; 13(5):1082-1089. PubMed ID: 37736932
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Imatinib-induced pyoderma gangrenosum in a patient with chronic myeloid leukemia.
    Faraci AG; Genovese G; Ferrucci S; Marzano AV
    Indian J Dermatol Venereol Leprol; 2021; 87(5):704-706. PubMed ID: 34114414
    [No Abstract]   [Full Text] [Related]  

  • 66. Correction to: Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis.
    Kantarjian HM; Hughes TP; Larson RA; Kim DW; Issaragrisil S; le Coutre P; Etienne G; Boquimpani C; Pasquini R; Clark RE; Dubruille V; Flinn IW; Kyrcz-Krzemien S; Medras E; Zanichelli M; Bendit I; Cacciatore S; Titorenko K; Aimone P; Saglio G; Hochhaus A
    Leukemia; 2021 Jul; 35(7):2142-2143. PubMed ID: 34108614
    [No Abstract]   [Full Text] [Related]  

  • 67. BCL-2 Inhibition as Treatment for Chronic Lymphocytic Leukemia.
    Perini GF; Feres CCP; Teixeira LLC; Hamerschlak N
    Curr Treat Options Oncol; 2021 Jun; 22(8):66. PubMed ID: 34110507
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Treatment of lymphocyte-variant hypereosinophilic syndrome (L-HES): what to consider after confirming the elusive diagnosis.
    Williams AK; Dou C; Chen LYC
    Br J Haematol; 2021 Dec; 195(5):669-680. PubMed ID: 34105142
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Italian Real-World Analysis of a Tyrosine Kinase Inhibitor Administration as First- or Second-Line of Therapy in Patients with Chronic Myeloid Leukemia.
    Perrone V; Giacomini E; Andretta M; Arenare L; Cillo MR; Latini M; Mecozzi A; Pagliaro R; Vercellone A; Degli Esposti L
    Ther Clin Risk Manag; 2021; 17():617-622. PubMed ID: 34135589
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Philadelphia chromosome-positive B-lymphoblastic lymphoma successfully treated with chemotherapy regimen containing imatinib: A rare case report and literature review.
    Li X; Cao W; Zhang S; Li L; Li Y; Jiang Z; Wan D; Yu J
    Medicine (Baltimore); 2021 Jun; 100(23):e26323. PubMed ID: 34115047
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Curative intent treatment of late presented extragastrointestinal stromal tumor: two identical case reports with literature review.
    Kadel D; Bhuju S; Thapa BR; Chalise S; Kumar Sah S
    J Surg Case Rep; 2021 Jun; 2021(6):rjab220. PubMed ID: 34104404
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Antiepileptic drugs and serotonin syndrome- A systematic review of case series and case reports.
    Prakash S; Rathore C; Rana K; Patel H
    Seizure; 2021 Oct; 91():117-131. PubMed ID: 34153897
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Unexpected pancytopenia: Dasatinib induced aplastic anemia in chronic myeloid leukemia.
    Feld J; Steinberg A; El Jamal SM; Shapira I
    J Oncol Pharm Pract; 2022 Jan; 28(1):232-236. PubMed ID: 34152210
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Association of SLC22A1,SLCO1B3 Drug Transporter Polymorphisms and Smoking with Disease Risk and Cytogenetic Response to Imatinib in Patients with Chronic Myeloid Leukemia.
    Mohammadi F; Rostami G; Assad D; Shafiei M; Hamid M; Jalaeikhoo H
    Lab Med; 2021 Nov; 52(6):584-596. PubMed ID: 34128532
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Perspectives and Emotional Experiences of Patients With Chronic Myeloid Leukemia During ENESTPath Clinical Trial and Treatment-Free Remission: Rationale and Protocol of the Italian Substudy.
    Borghi L; Rosti G; Maggi A; Breccia M; Di Bona E; Iurlo A; La Barba G; Sportoletti P; Albano F; Galimberti S; Rivellini F; Cambrin GR; Capodanno I; Cuneo A; Bonifacio M; Sica S; Arcaini L; Capochiani E; Minotto C; Ciceri F; Crugnola M; Di Caprio L; Supekar S; Elena C; Baccarani M; Vegni E
    Front Oncol; 2021; 11():638689. PubMed ID: 34123791
    [TBL] [Abstract][Full Text] [Related]  

  • 76. A Higher Dose of Dasatinib May Increase the Possibility of Crossing the Blood-brain Barrier in the Treatment of Patients With Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia.
    Gong X; Li L; Wei H; Liu B; Zhou C; Zhang G; Liu K; Lin D; Gong B; Wei S; Li Y; Mi Y; Wang Y; Wang J
    Clin Ther; 2021 Jul; 43(7):1265-1271.e1. PubMed ID: 34120773
    [TBL] [Abstract][Full Text] [Related]  

  • 77. A liver metastasis 7 years after resection of a low-risk duodenal gastrointestinal stromal tumor.
    Inoue M; Shishida M; Watanabe A; Kajikawa R; Kajiwara R; Sawada H; Ohmori I; Miyamoto K; Ikeda M; Toyota K; Sadamoto S; Takahashi T
    Clin J Gastroenterol; 2021 Oct; 14(5):1464-1469. PubMed ID: 34117599
    [TBL] [Abstract][Full Text] [Related]  

  • 78. IMiDs uniquely synergize with TKIs to upregulate apoptosis of Philadelphia chromosome-positive acute lymphoblastic leukemia cells expressing a dominant-negative IKZF1 isoform.
    Harama D; Yahata T; Kagami K; Abe M; Ando N; Kasai S; Tamai M; Akahane K; Inukai T; Kiyokawa N; Ibrahim AA; Ando K; Sugita K
    Cell Death Discov; 2021 Jun; 7(1):139. PubMed ID: 34117218
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Very Early-Onset Inflammatory Bowel Disease (VEO-IBD) Presenting with Recurrent Leukocytoclastic Vasculitis Preceded by Streptococcal Pharyngitis.
    Fonseca A; Sunny J; Felipez LM
    Case Rep Pediatr; 2021; 2021():1996430. PubMed ID: 34104503
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Novel pharmacological approach for the prevention of multidrug resistance (MDR) in a human leukemia cell line.
    Gupta SK; Singh P; Chhabra R; Verma M
    Leuk Res; 2021 Oct; 109():106641. PubMed ID: 34144313
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.